Insulin pump therapy is associated with higher rates of mild diabetic ketoacidosis compared to injection therapy: A 2-year Swedish national survey of children and adolescents with type 1 diabetes.
Adolescent
Child
Diabetes Mellitus, Type 1
/ drug therapy
Diabetic Ketoacidosis
/ chemically induced
Glycated Hemoglobin
/ metabolism
Humans
Hypoglycemic Agents
/ adverse effects
Injections, Subcutaneous
Insulin
/ adverse effects
Insulin Infusion Systems
/ adverse effects
Ketones
Sweden
/ epidemiology
child
diabetes mellitus type 1
diabetic ketoacidosis
insulin infusion systems
registries
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
31
05
2022
received:
09
03
2022
accepted:
07
06
2022
pubmed:
10
6
2022
medline:
19
10
2022
entrez:
9
6
2022
Statut:
ppublish
Résumé
Diabetic ketoacidosis (DKA) in type 1 diabetes (T1D) can occur during both insulin pump therapy (continuous subcutaneous insulin infusion, CSII) and insulin injection therapy (multiple daily injections, MDI). The primary aim of this study was to compare CSII and MDI regarding DKA frequency. A secondary aim was to compare metabolic derangement between CSII and MDI at hospital admission for DKA. RESEARCH DESIGN AND METHODS: Children 0-17.99 years with established T1D admitted for DKA in Sweden from February 1, 2015 to January 31, 2017 were invited to participate. Data regarding demographics, laboratory data, CSII or MDI, and access to ketone meters and CGM were provided through questionnaires and medical records. The Swedish National Diabetes Registry (SWEDIABKIDS) was used to compare the distribution of CSII and MDI in the national population with the population admitted for DKA, using the chi-square goodness-of-fit test. Distribution of CSII and MDI was then categorized in clinical severity grades for mild (pH 7.20-7.29), moderate (pH 7.10-7.29) and severe DKA (pH <7.10). The distribution of CSII at DKA admission was significantly larger than in the national pediatric population with T1D (74.7% vs. 59.7%, p = 0.002). CSII was overrepresented in mild DKA (85.2% vs. with CSII, p < 0.001), but not in moderate/severe DKA (57.9% with CSII, p = 0.82). Mean HbA1c at hospital admission was 73.9 mmol/mol with CSII and 102.7 mmol/mol with MDI. CSII was associated with higher risk of mild DKA than MDI. MDI was associated with markedly higher HbA1c levels than CSII at hospital admission for DKA.
Identifiants
pubmed: 35678764
doi: 10.1111/pedi.13377
pmc: PMC9796597
doi:
Substances chimiques
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Ketones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1044Informations de copyright
© 2022 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd.
Références
Pediatr Diabetes. 2009 Feb;10(1):33-7
pubmed: 18761647
J Diabetes Sci Technol. 2019 Sep;13(5):967-973
pubmed: 30628470
Pediatr Res. 2020 Mar;87(4):624-629
pubmed: 31715623
Nat Med. 2020 Sep;26(9):1380-1384
pubmed: 32908282
Pediatr Diabetes. 2021 Sep;22(6):900-908
pubmed: 33978305
Diabetes Care. 2019 Mar;42(3):443-449
pubmed: 30573652
Acta Biomed. 2019 May 23;90(2):215-220
pubmed: 31124998
Diabet Med. 2006 Mar;23(3):278-84
pubmed: 16492211
Pediatr Diabetes. 2022 Feb;23(1):38-44
pubmed: 34881493
Diabetes Care. 2016 Jun;39(6):e81-2
pubmed: 27208319
N Engl J Med. 2010 Jul 22;363(4):311-20
pubmed: 20587585
Diabet Med. 2013 Jul;30(7):818-24
pubmed: 23330615
Psychometrika. 2017 Dec;82(4):928-951
pubmed: 28290108
Pediatr Diabetes. 2018 Oct;19 Suppl 27:155-177
pubmed: 29900641
Pediatr Diabetes. 2018 Oct;19 Suppl 27:302-325
pubmed: 30039513
JAMA. 2017 Oct 10;318(14):1358-1366
pubmed: 29049584
Pediatr Diabetes. 2021 Aug;22(5):766-775
pubmed: 33929074
Diabetes Care. 2020 Nov;43(11):2768-2775
pubmed: 32962981
J Diabetes Sci Technol. 2017 May;11(3):631-632
pubmed: 27595713
N Engl J Med. 2020 Aug 27;383(9):836-845
pubmed: 32846062
Pediatr Diabetes. 2017 Nov;18(7):499-517
pubmed: 28726299
Diabetes Ther. 2021 Sep;12(9):2571-2583
pubmed: 34389930
Health Technol Assess. 2018 Aug;22(42):1-112
pubmed: 30109847
Lancet. 2018 Oct 13;392(10155):1321-1329
pubmed: 30292578
Pediatr Diabetes. 2013 Sep;14(6):447-54
pubmed: 23469984
Pediatr Diabetes. 2018 Oct;19 Suppl 27:115-135
pubmed: 29999222
Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S223-33
pubmed: 26784126
Pediatr Diabetes. 2016 Oct;17 Suppl 23:38-45
pubmed: 27417128
Diabetes Technol Ther. 2009 Aug;11(8):481-6
pubmed: 19698060
Diabetes Care. 2021 May;44(5):1176-1184
pubmed: 33653821
Pediatr Diabetes. 2015 Nov;16(7):546-53
pubmed: 25327782
Pediatr Diabetes. 2018 Nov;19(7):1271-1275
pubmed: 29923262
Pediatr Diabetes. 2022 Nov;23(7):1038-1044
pubmed: 35678764
Diabetes Care. 2015 Oct;38(10):1876-82
pubmed: 26283737
J Diabetes Sci Technol. 2015 Mar;9(2):209-14
pubmed: 25370149